NL-OMON41395CompletedNot Applicable
One-visit multi-site pre-exposure intradermal rabies vaccination: dose finding in healthy adults (R5). - R5
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •Subjects are required to fulfill all of the following criteria:
- •Age >= 18 years
- •Good health according to the investigator
- •Willingness and ability to adhere to the study regimen
- •Able to give informed consent
Exclusion Criteria
- •Exclusion criteria for this study are:
- •Known or suspected previous vaccination against rabies
- •Known or suspected allergy against any of the vaccine components
- •History of unusual or severe reactions to any previous vaccination
- •History of (pre)syncope associated with medical procedures involving needles
- •Immunocompromized state due to illness or medication
- •Administration of plasma or blood products three months prior to inclusion in the study
- •(hydroxy)chloroquine or mefloquine use
- •History of any neurological disorder including epilepsy or febrile seizures
- •Pregnancy or breastfeeding
- •Any current infectious disease other than seasonal cold
- •Bleeding disorders or use of anticoagulants
- •Temporary exclusion criterion for vaccination: Body temperature >= 38.5ºC or acute illness will lead to postponement of participation and vaccination. Screening may continue when the temperature has normalized.
Investigators
Similar Trials
Unknown
Phase 2
One-visit Multi-site Intradermal Rabies Vaccination - Dose FindingRabies Pre-exposure ProphylaxisNCT02276625Leiden University Medical Center30
Active, not recruiting
Not Applicable
A multi-centre, single intravenous dose, exploratory dose-finding, open label trial on the safety and efficacy of Sym001 in the treatment of Immune Thrombocytopenic Purpura (ITP) in RhD positive, non-splenectomized adult subjects - N/AEUCTR2007-006081-15-DESymphogen A/S66
Completed
Phase 2
A multi-centre, single intravenous dose, exploratory dose-finding, open label trial on the safety and efficacy of Sym001 in the treatment of Immune Thrombocytopenic Purpura (ITP) in RhD positive, non-splenectomized adult subjects.CTRI/2010/091/003049Symphogen AS66
Active, not recruiting
Phase 1
Sym001 in the treatment of rhesus D positive ITP patients who have not had their spleen removedEUCTR2007-006081-15-GBSymphogen A/S66
Active, not recruiting
Not Applicable
A multi-centre, single intravenous dose, exploratory dose-finding, open label trial on the safety and efficacy of Sym001 in the treatment of Immune Thrombocytopenic Purpura (ITP) in RhD positive, non-splenectomized adult subjects - N/AEUCTR2007-006081-15-BESymphogen A/S55